Additional Information

Description

Rinvoq® (upadacitinib) ER 45 mg tablet is an oral Janus kinase (JAK) inhibitor used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). Upadacitinib works by selectively inhibiting JAK1, an enzyme involved in the inflammatory response, which helps to reduce the symptoms of RA such as joint pain, swelling, and stiffness.

This extended-release formulation of Rinvoq® allows for a once-daily dose of 45 mg, improving patient adherence to the treatment regimen. The tablet is typically taken with or without food, with a consistent daily schedule recommended for optimal therapeutic outcomes. The dose may be adjusted based on individual patient needs and clinical response, as determined by a healthcare provider.

Common side effects of Rinvoq® include upper respiratory infections, headache, nausea, and high blood pressure. Serious side effects may include an increased risk of serious infections, blood clots, and certain types of cancer. Routine monitoring for adverse effects is necessary during treatment.